bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:BLUE
- CUSIP: N/A
- Web: www.bluebirdbio.com
Capitalization:- Market Cap: $4.35 billion
- Outstanding Shares: 45,589,000
Average Prices:- 50 Day Moving Avg: $96.14
- 200 Day Moving Avg: $91.42
- 52 Week Range: $37.05 - $123.75
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -13.95
- P/E Growth: 0.21
Sales & Book Value:- Annual Revenue: $26.65 million
- Price / Sales: 163.28
- Book Value: $26.35 per share
- Price / Book: 3.62
Profitability:- EBIDTA: ($259,890,000.00)
- Net Margins: -1,080.59%
- Return on Equity: -32.19%
- Return on Assets: -25.23%
Debt:- Current Ratio: 14.37%
- Quick Ratio: 14.37%
Misc:- Average Volume: 1.00 million shs.
- Beta: 2.09
- Short Ratio: 8.97
Frequently Asked Questions for bluebird bio (NASDAQ:BLUE)
What is bluebird bio's stock symbol?
bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."
How were bluebird bio's earnings last quarter?
bluebird bio, Inc. (NASDAQ:BLUE) posted its quarterly earnings results on Wednesday, August, 2nd. The company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.66) by $0.07. The company earned $16.70 million during the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company's revenue was up 977.4% on a year-over-year basis. During the same period in the prior year, the company earned ($1.59) earnings per share. View bluebird bio's Earnings History.
When will bluebird bio make its next earnings announcement?
Where is bluebird bio's stock going? Where will bluebird bio's stock price be in 2017?
19 brokerages have issued 12 month price objectives for bluebird bio's stock. Their forecasts range from $39.00 to $135.00. On average, they expect bluebird bio's stock price to reach $99.72 in the next year. View Analyst Ratings for bluebird bio.
What are analysts saying about bluebird bio stock?
Here are some recent quotes from research analysts about bluebird bio stock:
- 1. Cantor Fitzgerald analysts commented, "LentiGlobin R&D, A Costly Endeavor. From 2014 to 2016, LentiGlobin has accounted for approximately $127 million in direct R&D expenditures. While these expenditures for LentiGlobin have been substantial, they remain only a portion of total direct R&D ($240 million) and reported accounting R&D ($401 million). Given the 23 patients dosed with the gene therapy by ASH 2016, LentiGlobin amounted to an expense of $5.5 million per patient dosed. We estimate approximately 127 patients could be required to complete development for these programs, amounting to a cost of ~$700 million. We believe R&D estimates could accelerate and model for a slightly increased burn over future years." (7/24/2017)
- 2. According to Zacks Investment Research, "Bluebird Bio, Inc. is a biotechnology company. It focuses on the development, manufacture and marketing of therapies for severe genetic disorders such as childhood cerebral adrenoleukodystrophy, neurodegenerative disorders and beta-thalassemia. The company operates in the U.S. and Europe. Bluebird Bio, Inc. is headquartered in Cambridge, Massachusetts. " (7/18/2017)
- 3. BTIG Research analysts commented, "generally captured" data updates from ASCO and EHA. Positive On Outlook But Not Enough To Remain BullishMeanwhile, Bluebird has a "good lead" over the competition in drugs targeting anti-BCMA and a Phase 1 study of bb21217 will commence in the bottom half of 2017. But at the same time competitive efforts from rivals will also ramp up, including Kite Pharma Inc (NASDAQ: KITE), which will begin a study of a fully-human anti-BCMA CAR T therapy in the third quarter.The analyst remains "more optimistic than most" regarding the LentiGlobin program for Beta-thalassemia and Sickle-cell disease. Also, the company's broadening of its oncology efforts may be a source of concern among some investors but early success in bb2121 is indeed supportive of a "broader effort in larger markets with better defined patient populations." (6/30/2017)
- 4. Maxim Group analysts commented, "bluebird announced updated data at the ongoing ASCO (American Society of Clinical Oncology) meeting for bb2121 CAR-T in the CRB-401 Phase 1 study targeting relapsed/refractory multiple myeloma (r/r/ MM)." (6/2/2017)
Who are some of bluebird bio's key competitors?
Some companies that are related to bluebird bio include Exelixis (EXEL), Kite Pharma (KITE), TESARO (TSRO), Bioverativ (BIVV), Neurocrine Biosciences (NBIX), Clovis Oncology (CLVS), AveXis (AVXS), Juno Therapeutics (JUNO), Agios Pharmaceuticals (AGIO), BeiGene (BGNE), Intercept Pharmaceuticals (ICPT), GW Pharmaceuticals PLC (GWPH), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Spark Therapeutics (ONCE), Sarepta Therapeutics (SRPT), Loxo Oncology (LOXO) and Prothena Corporation PLC (PRTA).
Who are bluebird bio's key executives?
bluebird bio's management team includes the folowing people:
- Daniel S. Lynch, Independent Chairman of the Board
- Nick Leschly, President, Chief Executive Officer, Director
- Jeffrey T. Walsh, Chief Financial and Strategy Officer and Principal Financial Officer, Principal Accounting Officer
- Susanna Gatti High, Chief Operating Officer
- Eric M. Sullivan, Principal Accounting Officer, Vice President - Finance, Treasurer
- Philip D. Gregory Ph.D., Chief Scientific Officer
- David M. Davidson M.D., Chief Medical Officer
- Jason F. Cole Esq., Chief Legal Officer, Secretary
- John O. Agwunobi M.D., Director
- Douglas A. Melton, Director
Who owns bluebird bio stock?
bluebird bio's stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (14.73%), Capital Research Global Investors (12.03%), Baillie Gifford & Co. (11.86%), Vanguard Group Inc. (7.81%), BlackRock Inc. (7.29%) and State Street Corp (3.19%). Company insiders that own bluebird bio stock include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Nick Leschly and Philip D Gregory. View Institutional Ownership Trends for bluebird bio.
Who sold bluebird bio stock? Who is selling bluebird bio stock?
bluebird bio's stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Balyasny Asset Management LLC, State Street Corp, Columbus Circle Investors, Jennison Associates LLC, AXA, Candriam Luxembourg S.C.A. and Wells Fargo & Company MN. Company insiders that have sold bluebird bio stock in the last year include Daniel Lynch, David Davidson, Eric Sullivan, James Mandell, Jason Cole, Jeffrey T Walsh, John Maraganore, Nick Leschly and Philip D Gregory. View Insider Buying and Selling for bluebird bio.
Who bought bluebird bio stock? Who is buying bluebird bio stock?
bluebird bio's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Capital Research Global Investors, Vanguard Group Inc., Voya Investment Management LLC, Laurion Capital Management LP, Baillie Gifford & Co., Marshall Wace North America L.P. and BlackRock Inc.. View Insider Buying and Selling for bluebird bio.
How do I buy bluebird bio stock?
Shares of bluebird bio can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is bluebird bio's stock price today?
One share of bluebird bio stock can currently be purchased for approximately $95.45.
MarketBeat Community Rating for bluebird bio (NASDAQ BLUE)MarketBeat's community ratings are surveys of what our community members think about bluebird bio and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for bluebird bio (NASDAQ:BLUE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 2 Sell Ratings, 6 Hold Ratings, 11 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.47) |
| Consensus Price Target: | $99.72 (4.47% upside) |
Analysts' Ratings History for bluebird bio (NASDAQ:BLUE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/16/2017 | Evercore ISI | Initiated Coverage | In -> In-Line | $102.00 | High |  |
| 8/11/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $88.00 | Medium | |
| 8/9/2017 | Morgan Stanley | Reiterated Rating | Hold | | High | |
| 8/4/2017 | BMO Capital Markets | Reiterated Rating | Buy | $108.00 | Medium | |
| 7/27/2017 | Sanford C. Bernstein | Initiated Coverage | Market Perform | $109.00 | High | |
| 7/24/2017 | Cantor Fitzgerald | Reiterated Rating | Sell | $39.00 | High | |
| 6/30/2017 | BTIG Research | Downgrade | Buy -> Neutral | $37.05 -> $108.25 | Medium | |
| 6/26/2017 | Janney Montgomery Scott | Set Price Target | Buy | $125.00 | N/A | |
| 6/23/2017 | Cowen and Company | Reiterated Rating | Buy | | Low | |
| 6/23/2017 | Wedbush | Reiterated Rating | Outperform | $121.00 -> $100.00 | Low | |
| 6/16/2017 | Standpoint Research | Reiterated Rating | Buy -> Reduce | $110.00 | Low | |
| 6/5/2017 | Bank of America Corporation | Reiterated Rating | Hold | $95.00 | High | |
| 6/2/2017 | Maxim Group | Upgrade | Hold -> Buy | $100.00 | High | |
| 2/23/2017 | Roth Capital | Set Price Target | Hold | $71.00 | N/A | |
| 12/7/2016 | J P Morgan Chase & Co | Reiterated Rating | Buy | $120.00 | N/A | |
| 12/1/2016 | Leerink Swann | Boost Price Target | Outperform | $80.00 -> $85.00 | N/A | |
| 11/30/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $95.00 | N/A | |
| 10/15/2016 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Buy | $135.00 | N/A | |
| 10/14/2016 | SunTrust Banks, Inc. | Reiterated Rating | Buy | | N/A | |
| 5/5/2016 | Wells Fargo & Company | Reiterated Rating | Buy | | N/A | |
| 11/5/2015 | Oppenheimer Holdings, Inc. | Reiterated Rating | Outperform | $162.00 | N/A | |
(Data available from 8/22/2015 forward)
Earnings History for bluebird bio (NASDAQ:BLUE)Earnings History by Quarter for bluebird bio (NASDAQ BLUE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($1.68) | | | | | N/A | |
| 8/2/2017 | Q2 2017 | ($1.66) | ($1.73) | $6.29 million | $16.70 million | View | N/A | |
| 5/3/2017 | Q1 2017 | ($1.76) | ($1.68) | $1.51 million | $6.83 million | View | N/A | |
| 2/22/2017 | Q4 2016 | ($1.86) | ($1.88) | $1.76 million | $1.55 million | View | N/A | |
| 11/2/2016 | Q3 2016 | ($1.59) | ($2.07) | $1.82 million | $1.55 million | View | N/A | |
| 8/3/2016 | Q2 | ($1.44) | ($1.59) | $2.01 million | $1.55 million | View | N/A | |
| 5/4/2016 | Q1 | ($1.23) | ($1.52) | $4.50 million | $1.50 million | View | N/A | |
| 2/24/2016 | Q4 | ($1.11) | ($1.29) | $3.21 million | $1.47 million | View | N/A | |
| 11/4/2015 | Q3 | ($0.96) | ($1.18) | $5.63 million | $1.30 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.78) | ($1.57) | $8.60 million | $4.94 million | View | N/A | |
| 5/6/2015 | Q115 | ($0.68) | ($0.76) | $6.20 million | $6.30 million | View | N/A | |
| 2/25/2015 | Q414 | ($0.62) | ($0.66) | $6.20 million | $6.30 million | View | N/A | |
| 11/12/2014 | Q314 | ($0.52) | ($0.61) | $6.20 million | $6.40 million | View | N/A | |
| 8/12/2014 | Q214 | ($0.45) | ($0.06) | $6.15 million | $6.30 million | View | N/A | |
| 5/13/2014 | Q114 | ($0.32) | ($0.44) | $6.23 million | $6.30 million | View | N/A | |
| 3/5/2014 | | ($0.31) | ($0.34) | | | View | N/A | |
| 11/12/2013 | Q3 | ($0.25) | ($0.26) | $5.59 million | $6.39 million | View | N/A | |
| 8/8/2013 | Q213 | ($0.35) | ($2.13) | $4.85 million | $6.30 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for bluebird bio (NASDAQ:BLUE)2017 EPS Consensus Estimate: ($7.28)
2018 EPS Consensus Estimate: ($7.30)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 5 | ($1.88) | ($1.79) | ($1.83) |
| Q2 2017 | 5 | ($1.89) | ($1.60) | ($1.75) |
| Q3 2017 | 5 | ($1.94) | ($1.73) | ($1.82) |
| Q4 2017 | 5 | ($2.03) | ($1.78) | ($1.88) |
| Q1 2018 | 1 | ($1.78) | ($1.78) | ($1.78) |
| Q2 2018 | 1 | ($1.81) | ($1.81) | ($1.81) |
| Q3 2018 | 1 | ($1.84) | ($1.84) | ($1.84) |
| Q4 2018 | 1 | ($1.87) | ($1.87) | ($1.87) |
(Data provided by Zacks Investment Research)
Dividend History for bluebird bio (NASDAQ:BLUE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for bluebird bio (NASDAQ:BLUE)Insider Ownership Percentage: 3.90%
Insider Trades by Quarter for bluebird bio (NASDAQ:BLUE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/14/2017 | James Mandell | Director | Sell | 1,000 | $95.95 | $95,950.00 | |
| 8/10/2017 | Jeffrey T Walsh | Insider | Sell | 1,250 | $95.41 | $119,262.50 | |
| 8/7/2017 | Philip D Gregory | Insider | Sell | 750 | $99.00 | $74,250.00 | |
| 8/4/2017 | Eric Sullivan | Insider | Sell | 861 | $93.83 | $80,787.63 | |
| 8/1/2017 | David Davidson | Insider | Sell | 3,000 | $92.37 | $277,110.00 | |
| 7/10/2017 | Jeffrey T Walsh | Insider | Sell | 2,500 | $99.89 | $249,725.00 | |
| 7/7/2017 | David Davidson | Insider | Sell | 1,200 | $100.49 | $120,588.00 | |
| 7/6/2017 | Philip D Gregory | Insider | Sell | 2,250 | $103.83 | $233,617.50 | |
| 7/5/2017 | David Davidson | Insider | Sell | 5,000 | $105.28 | $526,400.00 | |
| 6/29/2017 | Eric Sullivan | Insider | Sell | 6,787 | $108.96 | $739,511.52 | |
| 6/27/2017 | Nick Leschly | Insider | Sell | 25,000 | $108.05 | $2,701,250.00 | |
| 6/23/2017 | Daniel Lynch | Director | Sell | 4,000 | $109.09 | $436,360.00 | |
| 6/20/2017 | Daniel Lynch | Director | Sell | 2,500 | $120.03 | $300,075.00 | |
| 6/7/2017 | Jason Cole | Insider | Sell | 17,245 | $100.22 | $1,728,293.90 | |
| 6/6/2017 | Daniel Lynch | Director | Sell | 2,263 | $100.14 | $226,616.82 | |
| 6/6/2017 | Philip D Gregory | Insider | Sell | 1,500 | $99.04 | $148,560.00 | |
| 6/5/2017 | David Davidson | Insider | Sell | 1,000 | $90.00 | $90,000.00 | |
| 5/25/2017 | Daniel Lynch | Director | Sell | 2,000 | $80.00 | $160,000.00 | |
| 4/27/2017 | Daniel Lynch | Director | Sell | 1,000 | $90.01 | $90,010.00 | |
| 4/25/2017 | Daniel Lynch | Director | Sell | 2,000 | $86.75 | $173,500.00 | |
| 4/10/2017 | Jeffrey T Walsh | Insider | Sell | 1,250 | $87.38 | $109,225.00 | |
| 4/3/2017 | David Davidson | Insider | Sell | 3,000 | $90.89 | $272,670.00 | |
| 3/27/2017 | Daniel Lynch | Director | Sell | 3,000 | $88.12 | $264,360.00 | |
| 3/16/2017 | Daniel Lynch | Director | Sell | 237 | $100.07 | $23,716.59 | |
| 3/16/2017 | Jason Cole | Insider | Sell | 4,930 | $100.07 | $493,345.10 | |
| 3/3/2017 | John Maraganore | Director | Sell | 13,839 | $85.02 | $1,176,591.78 | |
| 2/15/2017 | Daniel Lynch | Director | Sell | 150 | $80.22 | $12,033.00 | |
| 2/15/2017 | Jason Cole | Insider | Sell | 666 | $80.22 | $53,426.52 | |
| 2/14/2017 | Daniel Lynch | Director | Sell | 850 | $80.01 | $68,008.50 | |
| 2/14/2017 | Jason Cole | Insider | Sell | 3,772 | $80.01 | $301,797.72 | |
| 1/31/2017 | James Mandell | Director | Sell | 8,000 | $75.04 | $600,320.00 | |
| 1/27/2017 | Daniel Lynch | Director | Sell | 1,000 | $70.09 | $70,090.00 | |
| 1/27/2017 | David Davidson | Insider | Sell | 6,000 | $69.02 | $414,120.00 | |
| 1/5/2017 | Jason Cole | Insider | Sell | 549 | $67.10 | $36,837.90 | |
| 10/3/2016 | Eric Sullivan | Insider | Sell | 416 | $67.00 | $27,872.00 | |
| 9/13/2016 | Eric Sullivan | Insider | Sell | 416 | $59.00 | $24,544.00 | |
| 8/3/2016 | Eric Sullivan | Insider | Sell | 416 | $59.00 | $24,544.00 | |
| 7/27/2016 | Eric Sullivan | Insider | Sell | 2,912 | $55.01 | $160,189.12 | |
| 7/20/2016 | Eric Sullivan | Insider | Sell | 2,807 | $45.04 | $126,427.28 | |
| 7/15/2016 | David Davidson | Insider | Sell | 1,000 | $45.08 | $45,080.00 | |
| 6/16/2016 | Philip D Gregory | Insider | Sell | 2,931 | $39.52 | $115,833.12 | |
| 6/15/2016 | David Davidson | Insider | Sell | 1,000 | $40.11 | $40,110.00 | |
| 5/16/2016 | David Davidson | Insider | Sell | 1,000 | $38.73 | $38,730.00 | |
| 4/15/2016 | David Davidson | Insider | Sell | 1,000 | $49.63 | $49,630.00 | |
| 3/15/2016 | David Davidson | Insider | Sell | 1,000 | $46.13 | $46,130.00 | |
| 2/16/2016 | David Davidson | insider | Sell | 1,000 | $45.18 | $45,180.00 | |
| 1/15/2016 | David Davidson | insider | Sell | 1,000 | $44.39 | $44,390.00 | |
| 12/15/2015 | David Davidson | insider | Sell | 1,000 | $58.55 | $58,550.00 | |
| 12/8/2015 | Nick Leschly | CEO | Buy | 9,682 | $51.75 | $501,043.50 | |
| 11/16/2015 | David Davidson | insider | Sell | 2,000 | $70.99 | $141,980.00 | |
| 11/10/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $74.60 | $820,600.00 | |
| 10/15/2015 | David Davidson | insider | Sell | 2,000 | $79.70 | $159,400.00 | |
| 10/12/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $88.06 | $968,660.00 | |
| 10/9/2015 | Jason Cole | SVP | Sell | 5,000 | $86.91 | $434,550.00 | |
| 10/5/2015 | Daniel Lynch | Director | Sell | 3,000 | $100.41 | $301,230.00 | |
| 9/17/2015 | Daniel Lynch | Director | Sell | 1,500 | $140.06 | $210,090.00 | |
| 9/15/2015 | David Davidson | insider | Sell | 2,000 | $129.98 | $259,960.00 | |
| 9/10/2015 | Jeffrey T. Walsh | COO | Sell | 11,000 | $130.02 | $1,430,220.00 | |
| 9/9/2015 | Jason Cole | SVP | Sell | 2,000 | $136.56 | $273,120.00 | |
| 9/8/2015 | Daniel Lynch | Director | Sell | 7,000 | $132.75 | $929,250.00 | |
| 9/8/2015 | Nick Leschly | CEO | Sell | 125,000 | $135.24 | $16,905,000.00 | |
| 9/1/2015 | James Mandell | Director | Sell | 1,500 | $125.96 | $188,940.00 | |
| 7/20/2015 | Eric Sullivan | Insider | Sell | 1,126 | $163.36 | $183,943.36 | |
| 7/15/2015 | David Davidson | Insider | Sell | 2,000 | $165.96 | $331,920.00 | |
| 7/10/2015 | Jeffrey T Walsh | COO | Sell | 11,000 | $158.63 | $1,744,930.00 | |
| 7/9/2015 | Jason Cole | SVP | Sell | 5,000 | $158.19 | $790,950.00 | |
| 6/15/2015 | David Davidson | Insider | Sell | 2,000 | $183.34 | $366,680.00 | |
| 6/10/2015 | Jeffrey T Walsh | COO | Sell | 11,000 | $179.70 | $1,976,700.00 | |
| 6/1/2015 | Mitchell H Finer | Insider | Sell | 15,000 | $190.25 | $2,853,750.00 | |
| 4/20/2015 | Mitchell H Finer | Insider | Sell | 15,000 | $126.03 | $1,890,450.00 | |
| 4/15/2015 | David Davidson | Insider | Sell | 2,000 | $130.18 | $260,360.00 | |
| 4/10/2015 | Jeffrey T Walsh | COO | Sell | 21,000 | $126.21 | $2,650,410.00 | |
| 4/2/2015 | Eric Sullivan | Insider | Sell | 2,998 | $117.81 | $353,194.38 | |
| 3/10/2015 | Jeffrey T Walsh | COO | Sell | 10,500 | $110.06 | $1,155,630.00 | |
| 3/2/2015 | David Davidson | Insider | Sell | 4,000 | $94.84 | $379,360.00 | |
| 1/12/2015 | Jeffrey T Walsh | COO | Sell | 10,500 | $103.57 | $1,087,485.00 | |
| 1/2/2015 | David Davidson | Insider | Sell | 4,000 | $90.01 | $360,040.00 | |
| 12/19/2014 | John Maraganore | Director | Buy | 2,352 | $85.00 | $199,920.00 | |
| 12/10/2014 | Jeffrey T Walsh | COO | Sell | 43,500 | $78.06 | $3,395,610.00 | |
| 12/8/2014 | David Davidson | Insider | Sell | 15,000 | $46.10 | $691,500.00 | |
| 12/3/2014 | David Davidson | Insider | Sell | 3,000 | $41.65 | $124,950.00 | |
| 12/1/2014 | Mitchell H Finer | Insider | Sell | 18,000 | $39.70 | $714,600.00 | |
| 12/1/2014 | Nick Leschly | CEO | Sell | 2,417 | $39.70 | $95,954.90 | |
| 11/3/2014 | David Davidson | Insider | Sell | 3,000 | $41.68 | $125,040.00 | |
| 11/3/2014 | Nick Leschly | CEO | Sell | 25,000 | $41.68 | $1,042,000.00 | |
| 10/24/2014 | Nick Leschly | CEO | Sell | 33,900 | $40.22 | $1,363,458.00 | |
| 10/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $33.16 | $248,700.00 | |
| 10/9/2014 | Steven Gillis | Director | Sell | 115,000 | $35.25 | $4,053,750.00 | |
| 10/8/2014 | Mitchell H Finer | Insider | Sell | 34,518 | $33.52 | $1,157,043.36 | |
| 10/7/2014 | Steven Gillis | Director | Sell | 57,435 | $35.43 | $2,034,922.05 | |
| 10/2/2014 | Steven Gillis | Director | Sell | 91,165 | $35.28 | $3,216,301.20 | |
| 10/1/2014 | David Davidson | Insider | Sell | 3,000 | $34.55 | $103,650.00 | |
| 10/1/2014 | Nick Leschly | CEO | Sell | 8,000 | $34.55 | $276,400.00 | |
| 9/12/2014 | Robert I Tepper | Director | Sell | 125,000 | $36.54 | $4,567,500.00 | |
| 9/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $37.02 | $277,650.00 | |
| 9/2/2014 | David Davidson | Insider | Sell | 3,000 | $38.00 | $114,000.00 | |
| 9/2/2014 | Nick Leschly | CEO | Sell | 10,300 | $38.45 | $396,035.00 | |
| 8/11/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $34.26 | $256,950.00 | |
| 8/1/2014 | David Davidson | Insider | Sell | 3,000 | $33.62 | $100,860.00 | |
| 8/1/2014 | Nick Leschly | CEO | Sell | 8,000 | $33.62 | $268,960.00 | |
| 7/14/2014 | John Maraganore | Director | Buy | 2,941 | $34.00 | $99,994.00 | |
| 7/10/2014 | Jeffrey T Walsh | COO | Sell | 7,500 | $33.20 | $249,000.00 | |
| 7/3/2014 | Nick Leschly | CEO | Sell | 22,283 | $39.86 | $888,200.38 | |
| 7/1/2014 | David Davidson | Insider | Sell | 3,000 | $39.55 | $118,650.00 | |
| 6/20/2014 | Nick Leschly | CEO | Sell | 17,075 | $40.06 | $684,024.50 | |
| 6/16/2014 | Jeffrey T Walsh | COO | Sell | 1,500 | $39.86 | $59,790.00 | |
| 6/16/2014 | Mitchell H Finer | Insider | Sell | 10,000 | $39.84 | $398,400.00 | |
| 6/16/2014 | Nick Leschly | CEO | Sell | 42,925 | $40.02 | $1,717,858.50 | |
| 6/10/2014 | Jeffrey T Walsh | COO | Sell | 6,000 | $24.23 | $145,380.00 | |
| 6/2/2014 | Mitchell H Finer | Insider | Sell | 8,000 | $22.21 | $177,680.00 | |
| 6/2/2014 | Nick Leschly | CEO | Sell | 5,000 | $22.21 | $111,050.00 | |
| 5/14/2014 | Jeffrey Walsh | COO | Sell | 1,500 | $20.03 | $30,045.00 | |
| 5/12/2014 | Jeffrey Walsh | COO | Sell | 4,500 | $18.93 | $85,185.00 | |
| 5/1/2014 | David Davidson | Insider | Sell | 4,000 | $19.85 | $79,400.00 | |
| 5/1/2014 | Nick Leschly | CEO | Sell | 5,000 | $20.07 | $100,350.00 | |
| 4/10/2014 | Jeffrey Walsh | COO | Sell | 6,000 | $21.29 | $127,740.00 | |
| 1/22/2014 | Linda Bain | VP | Sell | 2,500 | $25.11 | $62,775.00 | |
| 1/17/2014 | Robert Tepper | Director | Sell | 307,000 | $22.43 | $6,886,010.00 | |
| 1/16/2014 | Mitchell Finer | Insider | Sell | 10,000 | $23.52 | $235,200.00 | |
| 1/14/2014 | Robert Tepper | Director | Sell | 340,000 | $21.90 | $7,446,000.00 | |
| 1/10/2014 | Jeffrey Walsh | COO | Sell | 6,000 | $21.98 | $131,880.00 | |
| 1/3/2014 | David Davidson | Insider | Sell | 15,000 | $20.88 | $313,200.00 | |
| 1/3/2014 | Linda Bain | VP | Sell | 5,000 | $20.89 | $104,450.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for bluebird bio (NASDAQ:BLUE)
Latest Headlines for bluebird bio (NASDAQ:BLUE)
| Source: |
|
| Date | Headline |
|---|
 | Brokerages Anticipate bluebird bio, Inc. (BLUE) Will Post Earnings of -$1.63 Per Share
www.americanbankingnews.com - August 20 at 6:16 AM |
| bluebird bio, Inc. (BLUE) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - August 19 at 1:14 PM |
| bluebird bio, Inc. (BLUE) Research Coverage Started at Evercore ISI
www.americanbankingnews.com - August 16 at 6:58 PM |
| bluebird bio, Inc. (BLUE) Director Sells $95,950.00 in Stock
www.americanbankingnews.com - August 15 at 8:02 PM |
| bluebird bio, Inc. (NASDAQ:BLUE) Insider Sells $119,262.50 in Stock
www.americanbankingnews.com - August 14 at 11:30 PM |
| bluebird bio, Inc. (BLUE) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - August 12 at 8:56 PM |
 | Is This Why bluebird bio Dipped 10.5% in July? - Motley Fool
www.fool.com - August 9 at 9:51 PM |
| bluebird bio, Inc. (BLUE) Earns Hold Rating from Morgan Stanley
www.americanbankingnews.com - August 9 at 5:56 PM |
| Insider Selling: bluebird bio, Inc. (BLUE) Insider Sells 750 Shares of Stock
www.americanbankingnews.com - August 9 at 4:52 PM |
 | bluebird bio to Present at Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 4:48 PM |
| Is This Why bluebird bio Dipped 10.5% in July?
finance.yahoo.com - August 9 at 4:48 PM |
 | Gene therapies getting closer to delivering on promise - Seeking Alpha
seekingalpha.com - August 8 at 4:22 PM |
| bluebird bio, Inc. – Value Analysis (NASDAQ:BLUE) : August 7, 2017
finance.yahoo.com - August 7 at 10:08 PM |
| bluebird bio Pauses During 2017 Data Blitz - Motley Fool
www.fool.com - August 7 at 5:08 PM |
| Price target changes - healthcare - Seeking Alpha
seekingalpha.com - August 7 at 5:08 PM |
| bluebird bio, Inc. (NASDAQ:BLUE) Insider Sells $80,787.63 in Stock
www.americanbankingnews.com - August 7 at 4:14 PM |
| bluebird bio, Inc. (NASDAQ:BLUE) Price Target Raised to $105.00 at Morgan Stanley
www.americanbankingnews.com - August 7 at 10:58 AM |
| Wedbush Analysts Lower Earnings Estimates for bluebird bio, Inc. (NASDAQ:BLUE)
www.americanbankingnews.com - August 7 at 8:08 AM |
| Leerink Swann Comments on bluebird bio, Inc.'s Q3 2017 Earnings (BLUE)
www.americanbankingnews.com - August 7 at 8:08 AM |
| $5.79 Million in Sales Expected for bluebird bio, Inc. (NASDAQ:BLUE) This Quarter
www.americanbankingnews.com - August 4 at 9:40 AM |
| Insider Selling: bluebird bio Inc (NASDAQ:BLUE) Insider Sells 3,000 Shares of Stock
www.americanbankingnews.com - August 3 at 8:40 PM |
| Bluebird reports 2Q loss
finance.yahoo.com - August 3 at 6:01 PM |
| bluebird bio, Inc. (BLUE) Issues Quarterly Earnings Results, Misses Estimates By $0.07 EPS
www.americanbankingnews.com - August 2 at 9:04 PM |
 | bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress - Business Wire (press release)
www.businesswire.com - August 2 at 5:22 PM |
| bluebird bio Reports Second Quarter 2017 Financial Results and Recent Operational Progress
finance.yahoo.com - August 2 at 5:22 PM |
| bluebird bio, Inc. Forecasted to Earn FY2017 Earnings of ($6.52) Per Share (NASDAQ:BLUE)
www.americanbankingnews.com - July 26 at 11:34 AM |
| bluebird bio, Inc. breached its 50 day moving average in a Bullish Manner : BLUE-US : July 25, 2017
finance.yahoo.com - July 25 at 4:29 PM |
| bluebird bio, Inc. (NASDAQ:BLUE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 25 at 12:53 PM |
| bluebird bio, Inc. (NASDAQ:BLUE) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:32 AM |
| ETFs with exposure to bluebird bio, Inc. : July 24, 2017
finance.yahoo.com - July 24 at 3:57 PM |
| bluebird bio, Inc. (NASDAQ:BLUE) Given "Sell" Rating at Cantor Fitzgerald
www.americanbankingnews.com - July 24 at 10:06 AM |
 | Commit To Buy bluebird bio At $50, Earn 10.4% Using Options
www.nasdaq.com - July 21 at 4:59 PM |
 | Sanderson Farms, Inc. Names Suzanne Mestayer To Board Of Directors
www.thestreet.com - July 20 at 6:11 PM |
| bluebird bio, Inc. (BLUE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - July 18 at 7:58 PM |
| ETFs with exposure to bluebird bio, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 6:30 PM |
 | Pioneering Cancer Gene Therapy by Novartis Backed by U.S. Panel
www.nytimes.com - July 13 at 10:36 PM |
 | FDA Backs Pioneering Gene-Altering Cancer Treatment - HuffPost
www.huffingtonpost.com - July 13 at 5:35 PM |
| Insider Selling: bluebird bio, Inc. (BLUE) Insider Sells 2,500 Shares of Stock
www.americanbankingnews.com - July 12 at 8:16 PM |
 | Opinion: Technical trading: These four stocks are breaking out of their pattern - MarketWatch
www.marketwatch.com - July 12 at 5:11 PM |
 | FDA panel backs Novartis' pioneering new cancer gene therapy - Reuters
www.reuters.com - July 12 at 5:11 PM |
| SunTrust bullish on bluebird bio - Seeking Alpha
seekingalpha.com - July 12 at 5:11 PM |
| Novartis Grabs Key FDA Panel Approval Of Experimental Cancer Drug
finance.yahoo.com - July 12 at 5:11 PM |
| bluebird bio, Inc. (NASDAQ:BLUE) Expected to Post Quarterly Sales of $5.70 Million
www.americanbankingnews.com - July 12 at 9:36 AM |
| A Junior Freak Out
www.nasdaq.com - July 12 at 2:57 AM |
| bluebird bio, Inc. (BLUE) Insider Sells $120,588.00 in Stock
www.americanbankingnews.com - July 11 at 8:20 PM |
| bluebird bio, Inc. breached its 50 day moving average in a Bearish Manner : BLUE-US : July 11, 2017
finance.yahoo.com - July 11 at 4:54 PM |
| Morgan Stanley Reiterates Equal Weight Rating for bluebird bio, Inc. (BLUE)
www.americanbankingnews.com - July 10 at 9:40 PM |
| Philip D. Gregory Sells 2,250 Shares of bluebird bio, Inc. (NASDAQ:BLUE) Stock
www.americanbankingnews.com - July 10 at 8:12 PM |
| -$1.63 Earnings Per Share Expected for bluebird bio, Inc. (NASDAQ:BLUE) This Quarter
www.americanbankingnews.com - July 10 at 8:10 PM |
| Insider Selling: bluebird bio, Inc. (BLUE) Insider Sells 5,000 Shares of Stock
www.americanbankingnews.com - July 7 at 8:16 PM |
bluebird bio (BLUE) Chart for Tuesday, August, 22, 2017
